Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/18 11:00:00 am
633.6 DKK   -0.85%
01/14Novo Nordisk Settles Securities Case in Denmark
MT
01/14Novo Nordisk announces settlement of securities lawsuit in Denmark
AQ
01/10Novo Nordisk A/S – Share repurchase programme
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Deutsche Bank reaffirms its Buy rating

11/29/2021 | 07:18am EST

In a research note, Deutsche Bank analyst Emmanuel Papadakis has maintained his recommendation on the stock with a Buy rating. The target price is unchanged at DKK 775.


ę MarketScreener with dpa-AFX Analyser 2021
All news about NOVO NORDISK A/S
01/14Novo Nordisk Settles Securities Case in Denmark
MT
01/14Novo Nordisk announces settlement of securities lawsuit in Denmark
AQ
01/10Novo Nordisk A/S – Share repurchase programme
AQ
01/062Seventy Bio Working With Novo Nordisk to Develop Potential Gene-Editing Treatment for ..
MT
01/062seventy bio, Inc. Announces Expanded Collaboration Agreement with Novo Nordisk to Cont..
CI
01/06NOVO NORDISK : Deutsche Bank remains Neutral
MD
01/06NOVO NORDISK : Receives a Sell rating from Jefferies
MD
01/05Humanwell Healthcare to Sell Entire RiteDose Stake For $174 Million; Shares Jump 3%
MT
01/04NOVO NORDISK : Gets a Neutral rating from JP Morgan
MD
01/04NOVO NORDISK : Bernstein reiterates its Buy rating
MD
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 140 B 21 269 M 21 269 M
Net income 2021 47 537 M 7 235 M 7 235 M
Net Debt 2021 1 027 M 156 M 156 M
P/E ratio 2021 30,9x
Yield 2021 1,59%
Capitalization 1 443 B 220 B 220 B
EV / Sales 2021 10,3x
EV / Sales 2022 9,40x
Nbr of Employees 46 982
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Last Close Price 639,00 DKK
Average target price 673,26 DKK
Spread / Average Target 5,36%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S-15.01%223 075
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317